NCT00720941 · OUTCOME
All Collected Deaths
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma · Source last updated 2025-03-30
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Pre-treatment deaths: Up to 21 days prior to treatment. On-treatment deaths: Up to 129 months. Post-treatment deaths: up to 152 months.
What was measured
Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication.
On-treatment deaths were collected from first dose of study medication to 28 days after last dose of study medication (on-treatment), up to approximately 129 months.
Deaths were collected in the post treatment survival follow up from 29 days after last dose of study medication until the end of the study, up to approximately 152 months.
Analysis population: Intent-to-Treat (ITT) Population
Groups in this outcome
Pazopanib 800 mg
Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
Sunitinib 50 mg
Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Pazopanib 800 mg | 557 |
|---|
| Sunitinib 50 mg | 553 |
|---|
Reported measurements
Pre-treatment deaths
Analysis denominator · Participants
| Group | Source count |
|---|
| Pazopanib 800 mg | 557 |
|---|
| Sunitinib 50 mg | 553 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Pazopanib 800 mg | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Sunitinib 50 mg | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
On-treatment deaths
Analysis denominator · Participants
| Group | Source count |
|---|
| Pazopanib 800 mg | 554 |
|---|
| Sunitinib 50 mg | 548 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Pazopanib 800 mg | 25 | Not reported | Not reported | Not reported | Not reported |
|---|
| Sunitinib 50 mg | 22 | Not reported | Not reported | Not reported | Not reported |
|---|
Post-treatment deaths
Analysis denominator · Participants
| Group | Source count |
|---|
| Pazopanib 800 mg | 529 |
|---|
| Sunitinib 50 mg | 526 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Pazopanib 800 mg | 310 | Not reported | Not reported | Not reported | Not reported |
|---|
| Sunitinib 50 mg | 312 | Not reported | Not reported | Not reported | Not reported |
|---|
All deaths
Analysis denominator · Participants
| Group | Source count |
|---|
| Pazopanib 800 mg | 557 |
|---|
| Sunitinib 50 mg | 553 |
|---|
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Pazopanib 800 mg | 335 | Not reported | Not reported | Not reported | Not reported |
|---|
| Sunitinib 50 mg | 334 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 557
- group Id
- OG001
- value
- 553
- units
- Participants
- title
- Pre-treatment deaths
- categories
- measurements
- group Id
- OG000
- value
- 25
- group Id
- OG001
- value
- 22
- denoms
- counts
- group Id
- OG000
- value
- 554
- group Id
- OG001
- value
- 548
- units
- Participants
- title
- On-treatment deaths
- categories
- measurements
- group Id
- OG000
- value
- 310
- group Id
- OG001
- value
- 312
- denoms
- counts
- group Id
- OG000
- value
- 529
- group Id
- OG001
- value
- 526
- units
- Participants
- title
- Post-treatment deaths
- categories
- measurements
- group Id
- OG000
- value
- 335
- group Id
- OG001
- value
- 334
- denoms
- counts
- group Id
- OG000
- value
- 557
- group Id
- OG001
- value
- 553
- units
- Participants
- title
- All deaths
- denoms
- counts
- group Id
- OG000
- value
- 557
- group Id
- OG001
- value
- 553
- units
- Participants
- description
- Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication.
On-treatment deaths were collected from first dose of study medication to 28 days after last dose of study medication (on-treatment), up to approximately 129 months.
Deaths were collected in the post treatment survival follow up from 29 days after last dose of study medication until the end of the study, up to approximately 152 months.
- groups
- description
- Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
- id
- OG000
- title
- Pazopanib 800 mg
- description
- Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
- id
- OG001
- title
- Sunitinib 50 mg
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Intent-to-Treat (ITT) Population
- reporting Status
- POSTED
- time Frame
- Pre-treatment deaths: Up to 21 days prior to treatment. On-treatment deaths: Up to 129 months. Post-treatment deaths: up to 152 months.
- title
- All Collected Deaths
- type
- OTHER_PRE_SPECIFIED
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle